Dr. Ehud Geller has served as the Chairman of the Regentis Board of Directors since 2007. He served as the General Partner of Medica Venture Partners. Between 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President and CEO of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel Institute, Philadelphia. Since 1995, he has been the General Partner of Medica Venture Partners. Mr. Geller was selected to serve on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical industry and his significant leadership experience.
Dr. Eli Hazum has served as Regentis’ Chief Executive Officer since October 2021. He has been a partner and Chief Scientific Officer of Medica Venture Partners since 1995. Prior to joining Medica, Prof. Hazum spent five years at Glaxo Inc. as Head of the Department of Receptor Research and Metabolic Diseases and as a member of the Corporate Committee for New Technology Identification in osteoporosis, worldwide. Mr. Hazum received his Ph.D. degree in the field of hormone biochemistry from the Weizmann Institute of Science, B.Sc and M.Sc degrees in Chemistry from Tel Aviv University and an executive MBA degree from Humberside University in the UK.
Mr. Arie Gordashnikov has been Regentis’ Chief Financial Officer since October 2022. He has served as Head of IPO & M&A Department at Shimony Yosef Certified Public Accountant (Isr.), or Shimony, since 2018. Mr. Gordashnikov has over 13 years’ experience in accounting, auditing and finance of Hi-Tech and biotechnology companies. Before joining Shimony, Mr. Gordashnikov was an audit manager at Ernst & Young Israel. Mr. Gordashnikov holds an MBA degree from Tel Aviv University in financial management, a B.A. in Accounting and Economics from Hebrew University of Jerusalem, and has been a licensed CPA since 2012.
Mr. Band has served as Regentis’ Chief Operating Officer since October 2021. Mr. Band served as the Chairman and CEO of Gix Internet Ltd. (formerly Algomizer Ltd.) from 2013 to 2020, (TASE:GIX) and as a Chairman of Viewbix (OTCMKTS: VBIX) from 2018 to 2020. Additionally, Mr. Band served as CEO of Timest, Mobillion, and Dotomi (acquired by ValueClick for $295 million). He holds an MBA, and a B.A. in Economics from The Hebrew University of Jerusalem. Mr. Band is also the vicechair for the non-profit Global Entrepreneurship Network (Israeli chapter), a judge in start-up competitions (Mass-Challenge, Get in The Ring, Start-up Open, Entrepreneur of The Year Award, Creative Business cup) and represents Israel in international conferences as a valuated member of the Start-up Nation.